Pharmaceutical Executive-02-01-2014

Pharmaceutical Executive
Country Report

February 10, 2014

Connecting the Dots The inclusion of healthcare as a priority on the presidential agenda has led to knock-on consequences that are being felt across the healthcare value chain in the Philippines. Universal healthcare coverage (UHC) has been cemented, which has led to a shift from branded medicines to generics, leading many players to a strategic repositioning. The most successful players have been those who focused on a strategy that was inclusive of all stakeholders and aligned with the presidential agenda of affordable and accessible healthcare.

Pharmaceutical Executive

Reflector looks at the growing pains of the European Medicine Agency (EMA) as it faces key policy challenges of 2014.

A patient-centric approach to drug development delivers the benefits that actually create value.

Pharmaceutical Executive
Column

February 01, 2014

Benefits offered by insurance plans on health exchanges and through Medicare are raising concerns about patient access to needed therapies, writes Jill Wechsler.

Pharmaceutical Executive
Column

February 01, 2014

For the first time, the spotlight shines on Russia's potential in biotechnology and pharma products

Pharmaceutical Executive
Features

February 01, 2014

Advocacy organizations and individual patients are getting more involved in every facet of the healthcare system, from drug R&D, to federal and state policy all fueled by the hour-to-hour passion of living with a disease.

Pharmaceutical Executive

For pharma marketers, the good news is recent advances in social media monitoring make it possible to listen to or engage with patients on social media websites.

Pharmaceutical Executive
Features

February 01, 2014

Millennium Takeda's new president, Anna Protopapas, explains the life choices that brought her from Cyprus to Cambridge-and a lead position in the hotly contested search to make cancer a treatable disease.

Pharmaceutical Executive
Features

February 01, 2014

Industry and market transformations have dramatically altered when and how products should be positioned for launch, writes Stan Bernard.

Pharmaceutical Executive
From the Editor

February 01, 2014

Today, there is promise in new approaches that rely on the "other language of biology," using the human body's own circuitry of cells and nerves to induce precisely targeted therapeutic effects against a range of debilitating diseases.